William E. Klunk

Q: What Schools Are Affiliated With William E. Klunk

William E. Klunk is affiliated with the following schools: University of Pittsburgh, Massachusetts General Hospital

William E. Klunk's AcademicInfluence.com Rankings

William E. Klunk

Medical

#1396

World Rank

#1729

Historical Rank

Neurology

#125

World Rank

#190

Historical Rank

medical Degrees

Download Badge

Medical

William E. Klunk's Degrees

Doctorate Medicine University of Pittsburgh

Why Is William E. Klunk Influential?

(Suggest an Edit or Addition)

According to Wikipedia, William E. Klunk is an American psychiatrist and neurologist currently the Distinguished Professor of Psychiatry and Neurology and Levidow-Pittsburgh Foundation Chair in Alzheimer's Disease and Dementia Disorders at University of Pittsburgh.

(See a Problem?)

William E. Klunk's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease (2011) (12716)
Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B (2004) (4136)
Clinical and biomarker changes in dominantly inherited Alzheimer's disease. (2012) (2815)
Molecular, Structural, and Functional Characterization of Alzheimer's Disease: Evidence for a Relationship between Default Activity, Amyloid, and Memory (2005) (1905)
Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. (2014) (1543)
Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. (2015) (1112)
Frequent amyloid deposition without significant cognitive impairment among the elderly. (2008) (978)
Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Aβ42 in humans (2006) (968)
Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents. (2003) (918)
Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease (2008) (888)
11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment. (2008) (876)
[11C]PIB in a nondemented population (2006) (767)
β-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease (2007) (719)
Longitudinal assessment of Aβ and cognition in aging and Alzheimer disease (2011) (718)
Fibrillar amyloid-β burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease (2009) (701)
Kinetic Modeling of Amyloid Binding in Humans using PET Imaging and Pittsburgh Compound-B (2005) (677)
Brain imaging in Alzheimer disease. (2012) (648)
Imaging β-amyloid burden in aging and dementia (2007) (610)
Quantitative evaluation of congo red binding to amyloid-like proteins with a beta-pleated sheet conformation. (1989) (575)
Validating novel tau positron emission tomography tracer [F‐18]‐AV‐1451 (T807) on postmortem brain tissue (2015) (553)
Consensus report of the working group on: 'Molecular and biochemical markers of Alzheimer's disease' (1998) (548)
Simplified quantification of Pittsburgh Compound B amyloid imaging PET studies: a comparative analysis. (2005) (546)
The Centiloid Project: Standardizing quantitative amyloid plaque estimation by PET (2015) (536)
Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer’s disease (2019) (487)
Prevalence of amyloid PET positivity in dementia syndromes: a meta-analysis. (2015) (476)
Imaging amyloid deposition in Lewy body diseases (2008) (434)
Dynamics of the Microglial/Amyloid Interaction Indicate a Role in Plaque Maintenance (2008) (418)
The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging and the Alzheimer's Association workgroup (2011) (410)
Uncharged thioflavin-T derivatives bind to amyloid-beta protein with high affinity and readily enter the brain. (2001) (410)
Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease. (2007) (409)
Imaging of amyloid burden and distribution in cerebral amyloid angiopathy (2007) (398)
Binding of the Positron Emission Tomography Tracer Pittsburgh Compound-B Reflects the Amount of Amyloid-β in Alzheimer's Disease Brain But Not in Transgenic Mouse Brain (2005) (384)
P2-366 Amyloid deposition begins in the striatum of presenilin-1 mutation carriers from two unrelated pedigrees (2006) (367)
Imaging Aβ Plaques in Living Transgenic Mice with Multiphoton Microscopy and Methoxy‐X04, a Systemically Administered Congo Red Derivative (2002) (364)
Molecular imaging with Pittsburgh Compound B confirmed at autopsy: a case report. (2007) (349)
11C-PIB PET imaging in Alzheimer disease and frontotemporal lobar degeneration (2007) (347)
Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab. (2012) (347)
A lipophilic thioflavin-T derivative for positron emission tomography (PET) imaging of amyloid in brain. (2002) (330)
Amyloid imaging in mild cognitive impairment subtypes (2009) (320)
Regional variability of imaging biomarkers in autosomal dominant Alzheimer’s disease (2013) (318)
Neuroimaging markers for the prediction and early diagnosis of Alzheimer's disease dementia (2011) (305)
Quantifying amyloid by congo red spectral shift assay. (1999) (300)
The Binding of 2-(4′-Methylaminophenyl)Benzothiazole to Postmortem Brain Homogenates Is Dominated by the Amyloid Component (2003) (293)
Dissecting phenotypic traits linked to human resilience to Alzheimer's pathology. (2013) (283)
In vivo optical imaging of amyloid aggregates in brain: design of fluorescent markers. (2005) (274)
Longitudinal cognitive decline is associated with fibrillar amyloid-beta measured by [11C]PiB (2010) (272)
Psychiatric symptoms vary with the severity of dementia in probable Alzheimer's disease. (2003) (264)
Quantifying Amyloid β-Peptide (Aβ) Aggregation Using the Congo Red-Aβ (CR–Aβ) Spectrophotometric Assay (1999) (254)
Four-dimensional multiphoton imaging of brain entry, amyloid binding, and clearance of an amyloid-β ligand in transgenic mice (2003) (253)
A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer’s disease (2020) (252)
11 C PiB and structural MRI provide complementary information in imaging of Alzheimer ’ s disease and amnestic mild cognitive impairment (2008) (240)
Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer disease (2009) (238)
X-34, A Fluorescent Derivative of Congo Red: A Novel Histochemical Stain for Alzheimer's Disease Pathology (2000) (232)
Accuracy of four clinical diagnostic criteria for the diagnosis of neurodegenerative dementias (1999) (229)
Absence of Pittsburgh compound B detection of cerebral amyloid beta in a patient with clinical, cognitive, and cerebrospinal fluid markers of Alzheimer disease: a case report. (2009) (217)
The Role of Biomarkers in Clinical Trials for Alzheimer Disease (2006) (216)
Imaging β-Amyloid Plaques and Neurofibrillary Tangles in the Aging Human Brain (2004) (212)
Basal Cerebral Metabolism May Modulate the Cognitive Effects of Aβ in Mild Cognitive Impairment: An Example of Brain Reserve (2009) (212)
Alzheimer's disease phenotypes and genotypes associated with mutations in presenilin 2. (2010) (202)
Imaging of amyloid plaques and cerebral glucose metabolism in semantic dementia and Alzheimer’s disease (2008) (199)
Developing an international network for Alzheimer research: The Dominantly Inherited Alzheimer Network. (2012) (186)
Anti-Abeta antibody treatment promotes the rapid recovery of amyloid-associated neuritic dystrophy in PDAPP transgenic mice. (2005) (185)
Partial volume correction in quantitative amyloid imaging (2015) (182)
Alterations of cerebral metabolism in probable Alzheimer's disease: A preliminary study (1994) (179)
Early detection of Alzheimer's disease using PiB and FDG PET (2014) (178)
Development of small molecule probes for the Beta-amyloid protein of Alzheimer's Disease (1994) (177)
Pathological correlations of [F‐18]‐AV‐1451 imaging in non‐alzheimer tauopathies (2017) (173)
Carbon 11-labeled Pittsburgh Compound B and carbon 11-labeled (R)-PK11195 positron emission tomographic imaging in Alzheimer disease. (2009) (168)
Longitudinal cognitive and biomarker changes in dominantly inherited Alzheimer disease (2018) (163)
Amyloid burden and neural function in people at risk for Alzheimer's Disease (2014) (157)
Clinical and neurochemical effects of acetyl-L-carnitine in Alzheimer's disease (1995) (156)
Development of positron emission tomography β-amyloid plaque imaging agents. (2012) (152)
Pulse wave velocity is associated with β-amyloid deposition in the brains of very elderly adults (2013) (150)
Research evaluation and diagnosis of possible Alzheimer’s disease over the last two decades: II (2000) (149)
N‐acetyl‐L‐aspartate and other amino acid metabolites in Alzheimer's disease brain (1992) (146)
Visualization of fibrillar amyloid deposits in living, transgenic Caenorhabditis elegans animals using the sensitive amyloid dye, X-34 (2001) (146)
Arterial stiffness and β-amyloid progression in nondemented elderly adults. (2014) (146)
Imaging of CNS myelin by positron-emission tomography. (2006) (145)
Research evaluation and prospective diagnosis of dementia with Lewy bodies. (2002) (143)
Amyloid imaging with carbon 11-labeled Pittsburgh compound B for traumatic brain injury. (2014) (134)
PK11195 labels activated microglia in Alzheimer's disease and in vivo in a mouse model using PET (2009) (131)
Amyloid-β 11C-PiB-PET imaging results from 2 randomized bapineuzumab phase 3 AD trials (2015) (130)
Imaging Alzheimer Pathology in Late-Life Depression With PET and Pittsburgh Compound-B (2008) (129)
Preclinical trials in autosomal dominant AD: implementation of the DIAN-TU trial. (2013) (127)
Evaluation of voxel-based methods for the statistical analysis of PIB PET amyloid imaging studies in Alzheimer's disease (2006) (124)
Research evaluation and diagnosis of probable Alzheimer’s disease over the last two decades: I (2000) (123)
Amyloid imaging as a biomarker for cerebral β-amyloidosis and risk prediction for Alzheimer dementia (2011) (122)
Multisite study of the relationships between antemortem [11C]PIB-PET Centiloid values and postmortem measures of Alzheimer's disease neuropathology (2018) (118)
Imaging brain amyloid in nondemented young adults with Down syndrome using Pittsburgh compound B (2012) (117)
Association of Cerebral Amyloid-&bgr; Aggregation With Cognitive Functioning in Persons Without Dementia (2018) (116)
Chrysamine-G binding to Alzheimer and control brain: Autopsy study of a new amyloid probe (1995) (114)
Consideration of Optimal Time Window for Pittsburgh Compound B PET Summed Uptake Measurements (2009) (114)
Impact of amyloid imaging on drug development in Alzheimer's disease. (2007) (112)
Regional amyloid burden and intrinsic connectivity networks in cognitively normal elderly subjects. (2014) (111)
Alteration of a Clinically Meaningful Outcome in the Natural History of Alzheimer's Disease by Cholinesterase Inhibition (2005) (110)
The 5-HTTPR Polymorphism Confers Liability to a Combined Phenotype of Psychotic and Aggressive Behavior in Alzheimer Disease (2001) (109)
Subjective Cognitive Complaints, Personality and Brain Amyloid-beta in Cognitively Normal Older Adults. (2015) (108)
The long-term effects of conventional and atypical antipsychotics in patients with probable Alzheimer's disease. (2013) (107)
Reliability of NINDS‐AIREN clinical criteria for the diagnosis of vascular dementia (1994) (106)
Two simple methods for quantifying low-affinity dye-substrate binding. (1989) (106)
Correspondence between in vivo 11C-PiB-PET amyloid imaging and postmortem, region-matched assessment of plaques (2012) (101)
In vivo fibrillar beta-amyloid detected using [11C]PiB positron emission tomography and neuropathologic assessment in older adults. (2011) (101)
Progression of Cerebral Amyloid Load Is Associated with the Apolipoprotein E ε4 Genotype in Alzheimer's Disease (2010) (100)
The 5-HTTPR*S/*L polymorphism and aggressive behavior in Alzheimer disease. (2001) (99)
Imaging Amyloid-β Deposits In Vivo (2002) (96)
Plasma Biosignature and Brain Pathology related to Persistent Cognitive Impairment in Late-Life Depression (2014) (95)
Phosphocreatine-dependent Glutamate Uptake by Synaptic Vesicles (1996) (94)
Longitudinal assessment of neuroimaging and clinical markers in autosomal dominant Alzheimer's disease: a prospective cohort study (2015) (94)
In vivo assessment of amyloid‐β deposition in nondemented very elderly subjects (2013) (92)
Using a reference tissue model with spatial constraint to quantify [11C]Pittsburgh compound B PET for early diagnosis of Alzheimer's disease (2007) (92)
Imaging the pathology of Alzheimer's disease: amyloid-imaging with positron emission tomography. (2003) (91)
The future of amyloid-beta imaging: a tale of radionuclides and tracer proliferation (2008) (90)
11 CPIB PET imaging in Alzheimer disease and frontotemporal lobar degeneration (2007) (90)
Plasma and cerebrospinal fluid α1‐antichymotrypsin levels in Alzheimer's disease: Correlation with cognitive impairment (2003) (88)
Using Pittsburgh Compound B for in vivo PET imaging of fibrillar amyloid-beta. (2012) (84)
Cognitive functioning in relation to brain amyloid-β in healthy adults with Down syndrome. (2014) (83)
Early AD pathology in a [C-11]PiB-negative case: a PiB-amyloid imaging, biochemical, and immunohistochemical study (2012) (83)
Standardization of amyloid quantitation with florbetapir standardized uptake value ratios to the Centiloid scale (2018) (82)
Analysis of magnetic resonance spectra by mole percent: Comparison to absolute units (1994) (80)
Inhibition of Polyglutamine Aggregation in R6/2 HD Brain Slices—Complex Dose–Response Profiles (2001) (78)
Chrysamine-G, a lipophilic analogue of Congo red, inhibits A beta-induced toxicity in PC12 cells. (1998) (78)
Precuneus amyloid burden is associated with reduced cholinergic activity in Alzheimer disease (2011) (76)
Quantitative 1H and 31P MRS of PCA extracts of postmortem Alzheimer's disease brain (1996) (76)
Characterizing regional correlation, laterality and symmetry of amyloid deposition in mild cognitive impairment and Alzheimer's disease with Pittsburgh Compound B (2008) (76)
Amyloid-β Imaging in Older Adults Presenting to a Memory Clinic with Subjective Cognitive Decline: A Pilot Study. (2015) (75)
Post-mortem histopathology underlying β-amyloid PET imaging following flutemetamol F 18 injection (2016) (75)
Small-molecule PET Tracers for Imaging Proteinopathies. (2017) (74)
Classification of amyloid-positivity in controls: Comparison of visual read and quantitative approaches (2013) (74)
Cognitive trajectories associated with β-amyloid deposition in the oldest-old without dementia (2013) (74)
Changes in brain membrane phospholipid and high-energy phosphate metabolism precede dementia (1995) (73)
Fluid and PET biomarkers for amyloid pathology in Alzheimer's disease (2019) (73)
Quantifying amyloid beta-peptide (Abeta) aggregation using the Congo red-Abeta (CR-abeta) spectrophotometric assay. (1999) (72)
Incidental Cerebral Microbleeds and Cerebral Blood Flow in Elderly Individuals. (2015) (71)
Imaging beta-amyloid plaques and neurofibrillary tangles in the aging human brain. (2004) (71)
Imaging technology for neurodegenerative diseases: progress toward detection of specific pathologies. (2005) (71)
Longitudinal Cerebral Blood Flow and Amyloid Deposition: An Emerging Pattern? (2008) (70)
Markers of cholesterol transport are associated with amyloid deposition in the brain (2014) (70)
Update on amyloid imaging: From healthy aging to Alzheimer’s disease (2009) (69)
Comparison of Pittsburgh compound B and florbetapir in cross-sectional and longitudinal studies (2019) (66)
2014 Report on the Milestones for the US National Plan to Address Alzheimer's Disease (2014) (65)
The effects of normal aging on amyloid-β deposition in nondemented adults with Down syndrome as imaged by carbon 11–labeled Pittsburgh compound B (2016) (64)
Distinct cytokine profiles in human brains resilient to Alzheimer's pathology (2019) (64)
The Road Ahead to Cure Alzheimer's Disease: Development of Biological Markers and Neuroimaging Methods for Prevention Trials Across all Stages and Target Populations. (2014) (63)
Relative 11C-PiB Delivery as a Proxy of Relative CBF: Quantitative Evaluation Using Single-Session 15O-Water and 11C-PiB PET (2015) (62)
Development of a PET/SPECT agent for amyloid imaging in Alzheimer’s disease (2007) (61)
Psychosis in Alzheimer disease: postmortem magnetic resonance spectroscopy evidence of excess neuronal and membrane phospholipid pathology (2002) (60)
[F‐18]AV‐1451 positron emission tomography retention in choroid plexus: More than “off‐target” binding (2016) (59)
Magnetic Resonance Spectroscopic Changes in Alzheimer's Disease a (1997) (58)
Association of Brain Amyloid-&bgr; With Slow Gait in Elderly Individuals Without Dementia: Influence of Cognition and Apolipoprotein E &egr;4 Genotype (2017) (56)
Psychotic Symptoms in Alzheimer's Disease Are Not Associated With More Severe Neuropathologic Features (2000) (55)
Computer-assisted modeling of the picrotoxinin and gamma-butyrolactone receptor site. (1983) (54)
Biological Markers of Alzheimer’s Disease (1998) (54)
Utilizing the Centiloid scale in cross-sectional and longitudinal PiB PET studies (2018) (53)
Longitudinal changes in amyloid positron emission tomography and volumetric magnetic resonance imaging in the nondemented Down syndrome population (2017) (52)
Prevalence of the apolipoprotein E ε4 allele in amyloid β positive subjects across the spectrum of Alzheimer's disease (2017) (52)
Comparison of qualitative and quantitative imaging characteristics of [11C]PiB and [18F]flutemetamol in normal control and Alzheimer's subjects (2015) (52)
Aβ Imaging: feasible, pertinent, and vital to progress in Alzheimer’s disease (2012) (52)
Cognitive decline and brain amyloid-β accumulation across 3 years in adults with Down syndrome (2017) (52)
Metabolic alterations in postmortem Alzheimer’s disease brain are exaggerated by Apo-E4 (1998) (51)
X-34 labeling of abnormal protein aggregates during the progression of Alzheimer's disease. (2006) (51)
Amyloid, neurodegeneration, and small vessel disease as predictors of dementia in the oldest-old (2014) (51)
Positron emission tomography radioligands for in vivo imaging of Aβ plaques. (2013) (51)
Apolipoprotein D is a component of compact but not diffuse amyloid-beta plaques in Alzheimer's disease temporal cortex (2005) (51)
Effects of lipophilicity on the affinity and nonspecific binding of iodinated benzothiazole derivatives (2007) (50)
Amyloid imaging in dementias with atypical presentation (2012) (50)
Inter-rater reliability of manual and automated region-of-interest delineation for PiB PET (2010) (50)
Hyperphosphorylated tau is elevated in Alzheimer's disease with psychosis. (2014) (47)
Quantitative Amyloid Imaging in Autosomal Dominant Alzheimer’s Disease: Results from the DIAN Study Group (2016) (46)
More evidence for association of a rare TREM2 mutation (R47H) with Alzheimer's disease risk (2015) (45)
Synthesis and evaluation of 2-(3′-lodo-4′-aminophenyl)-6-hydroxybenzothiazole for in vivo quantitation of amyloid deposits in alzheimer’s disease (2002) (45)
Early striatal amyloid deposition distinguishes Down syndrome and autosomal dominant Alzheimer's disease from late-onset amyloid deposition (2018) (45)
β-Amyloid 42/40 ratio and kalirin expression in Alzheimer disease with psychosis (2012) (44)
Imaging amyloid-beta deposits in vivo. (2002) (44)
Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum. (2022) (44)
Early risk assessment for Alzheimer's disease (2009) (42)
Lack of association between 11C-PiB and longitudinal brain atrophy in non-demented older individuals (2011) (42)
Cognitive and behavioral correlates of low vitamin B12 levels in elderly patients with progressive dementia. (2002) (41)
Disclosure of amyloid imaging results to research participants: Has the time come? (2013) (39)
b -amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer’s disease (2007) (39)
Cerebral perfusion alterations and cerebral amyloid in autosomal dominant Alzheimer disease (2014) (39)
Synthesis and beta-amyloid binding properties of rhenium 2-phenylbenzothiazoles. (2009) (35)
Dendritic spine density, morphology, and fibrillar actin content surrounding amyloid-β plaques in a mouse model of amyloid-β deposition. (2013) (35)
Genome-wide association study of brain amyloid deposition as measured by Pittsburgh Compound-B (PiB)-PET imaging (2018) (35)
Cognitive aging in persons with minimal amyloid-β and white matter hyperintensities (2013) (33)
L‐Phosphoserine, a Metabolite Elevated in Alzheimer's Disease, Interacts with Specific L‐Glutamate Receptor Subtypes (1991) (32)
The Alzheimer's Biomarker Consortium‐Down Syndrome: Rationale and methodology (2020) (31)
Targeting Prion Amyloid Deposits In Vivo (2004) (31)
Neuropathological correlates of amyloid PET imaging in Down syndrome (2019) (31)
Anticonvulsant properties of alpha, gamma, and alpha, gamma-substituted gamma-butyrolactones. (1982) (31)
Amyloid deposition and brain structure as long-term predictors of MCI, dementia, and mortality (2018) (30)
Amyloid &bgr; Deposition and Suspected Non-Alzheimer Pathophysiology and Cognitive Decline Patterns for 12 Years in Oldest Old Participants Without Dementia (2018) (30)
Soluble TREM2 in CSF and its association with other biomarkers and cognition in autosomal-dominant Alzheimer's disease: a longitudinal observational study (2022) (29)
Aggregation of β‐Amyloid Peptide Is Promoted by Membrane Phospholipid Metabolites Elevated in Alzheimer's Disease Brain (1997) (28)
Two-year follow-up of amyloid deposition in patients with Alzheimer's disease. (2006) (27)
Reduced binding of Pittsburgh Compound-B in areas of white matter hyperintensities (2015) (25)
Role of biomarkers in studies of presymptomatic Alzheimer’s disease (2005) (25)
Comparison of the amyloid imaging agents [F-18]3'-F-PIB and [C-11]PIB in Alzheimer's disease and control subjects (2007) (25)
Accelerated functional brain aging in pre-clinical familial Alzheimer’s disease (2021) (25)
Sleep moderates the relationship between amyloid beta and memory recall (2018) (25)
Alzheimer's β‐Amyloid Protein Is Covalently Modified when Dissolved in Formic Acid (1990) (25)
Investigating gains in neurocognition in an Intervention Trial of Exercise (IGNITE): Protocol. (2019) (24)
Anti-Amyloid Effects of Small Molecule Aβ-Binding Agents in PS1/APP Mice. (2009) (23)
Molecular insights into neurodevelopmental and neurodegenerative diseases (2000) (23)
IMPROVING BRAIN AGE PREDICTION MODELS: INCORPORATION OF AMYLOID STATUS IN ALZHEIMER’S DISEASE (2019) (23)
Structure-activity relationships of alkyl-substituted gamma-butyrolactones and succinimides. (1982) (22)
Alzheimer-Like Pattern of Hypometabolism Emerges with Elevated Amyloid-β Burden in Down Syndrome. (2017) (22)
Post-mortem analyses of PiB and flutemetamol in diffuse and cored amyloid-β plaques in Alzheimer’s disease (2020) (22)
Parenchymal border macrophages regulate the flow dynamics of the cerebrospinal fluid (2022) (22)
Possible roles of L-phosphoserine in the pathogenesis of Alzheimer's disease. (1991) (22)
Comparison of epileptogenic properties of unsubstituted and beta-alkyl-substituted gamma-butyrolactones. (1982) (22)
A multi-scanner neuroimaging data harmonization using RAVEL and ComBat (2021) (21)
Imaging Tau Deposits In Vivo: Progress in Viewing More of The Proteopathy Picture (2013) (21)
Measuring target effect of proposed disease-modifying therapies in Alzheimer’s disease (2008) (21)
Direct Comparison of the Tau PET Tracers 18F-Flortaucipir and 18F-MK-6240 in Human Subjects (2021) (21)
The use of Centiloids for applying [11C]PiB classification cutoffs across region-of-interest delineation methods (2018) (21)
Tenascin-C Is Associated with Cored Amyloid-&bgr; Plaques in Alzheimer Disease and Pathology Burdened Cognitively Normal Elderly (2016) (21)
Apolipoprotein E and Alpha-1-Antichymotrypsin Genotypes Do Not Predict Time to Psychosis in Alzheimer's Disease (2002) (20)
Alpha-substituted gamma-butyrolactones: new class of anticonvulsant drugs. (1982) (20)
Alzheimer's Disease: Membrane‐Associated Metabolic Changes a (1994) (19)
Aluminum and Health (1990) (19)
Amyloid accumulation in Down syndrome measured with amyloid load (2020) (19)
Synthesis and 11C-labelling of (E,E)-1-(3′,4′-dihydroxystyryl)-4-(3′-methoxy-4′-hydroxystyryl) benzene for PET imaging of amyloid deposits†† (2002) (19)
Design, synthesis and structure-activity relationship of rhenium 2-arylbenzothiazoles as β-amyloid plaque binding agents. (2013) (19)
Patterns of change in the treatment of psychiatric symptoms in patients with probable Alzheimer's disease from 1983 to 2000. (2003) (19)
Plasma Total-Tau and Neurofilament Light Chain as Diagnostic Biomarkers of Alzheimer's Disease Dementia and Mild Cognitive Impairment in Adults with Down Syndrome. (2020) (18)
Radiosynthesis, In Vitro and In Vivo Evaluation of [18F]CBD-2115 as a First-in-Class Radiotracer for Imaging 4R-Tauopathies. (2021) (18)
NMR Identification of the Formic Acid‐Modified Residue in Alzheimer's Amyloid Protein (1994) (18)
Chrysamine G and its derivative reduce amyloid β-induced neurotoxicity in mice (2002) (18)
Why we need two cutoffs for amyloid imaging: Early versus Alzheimer's-like amyloid-positivity (2012) (17)
Imaging neurodegeneration in Down syndrome: brain templates for amyloid burden and tissue segmentation (2018) (17)
Comparison of CSF biomarkers in Down syndrome and autosomal dominant Alzheimer's disease: a cross-sectional study (2021) (17)
Development and Screening of Contrast Agents for In Vivo Imaging of Parkinson’s Disease (2013) (17)
Metabolic correlates of prevalent mild cognitive impairment and Alzheimer's disease in adults with Down syndrome (2020) (17)
Variant-dependent heterogeneity in amyloid β burden in autosomal dominant Alzheimer's disease: cross-sectional and longitudinal analyses of an observational study (2022) (17)
Biomarkers for the early diagnosis of Alzheimer's disease (2006) (16)
Magnetic resonance spectroscopy and its application to aging and Alzheimer's disease. (1995) (16)
Erratum to “Preclinical trials in autosomal dominant AD: Implementation of the DIAN-TU trial” [Rev. Neurol. 169 (10) (2013) 737–743] (2013) (16)
Associations between NIH Toolbox Cognition Battery and in vivo brain amyloid and tau pathology in non‐demented older adults (2020) (16)
Astrocyte biomarker signatures of amyloid-β and tau pathologies in Alzheimer’s disease (2022) (16)
Cognitive indicators of transition to preclinical and prodromal stages of Alzheimer's disease in Down syndrome (2020) (16)
Association of sleep with cognition and beta amyloid accumulation in adults with Down syndrome (2020) (15)
Utility of perfusion PET measures to assess neuronal injury in Alzheimer's disease (2018) (15)
Development of a Standardized Approach to Disclosing Amyloid Imaging Research Results in Mild Cognitive Impairment. (2016) (15)
Lipophilic 11C‐labelled thioflavin‐T analogues for imaging amyloid plaques in alzheimer's disease (2001) (15)
Amyloid-Beta Deposition is Associated with Increased Medial Temporal Lobe Activation during Memory Encoding in the Cognitively Normal Elderly. (2017) (14)
P2-031 Amyloid deposits in transgenic PS1/APP mice do not bind the amyloid pet tracer, PIB, in the same manner as human brain amyloid (2004) (14)
Influence of apolipoprotein-E genotype on brain amyloid load and longitudinal trajectories (2020) (14)
Synthesis and evaluation of 2-(3'-iodo-4'-aminophenyl)-6-hydroxybenzothiazole for in vivo quantitation of amyloid deposits in Alzheimer's disease. (2002) (14)
Right lateral prefrontal cortex—specificity for inhibition or strategy use? (2015) (14)
Cerebrospinal fluid biomarkers of Alzheimer's disease in a cohort of adults with Down syndrome (2020) (14)
Cerebral Amyloid Deposition and Dual-Tasking in Cognitively Normal, Mobility Unimpaired Older Adults (2016) (14)
What Is T+? A Gordian Knot of Tracers, Thresholds, and Topographies (2020) (14)
Proteomic profiles for Alzheimer's disease and mild cognitive impairment among adults with Down syndrome spanning serum and plasma: An Alzheimer's Biomarker Consortium–Down Syndrome (ABC–DS) study (2020) (14)
Inactivity of phosphoethanolamine, an endogenous GABA analog decreased in Alzheimer's disease, at GABA binding sites. (1995) (13)
Longitudinal trajectories of amyloid deposition, cortical thickness, and tau in Down syndrome: A deep-phenotyping case report (2019) (13)
Molecular imaging: What is right and what is an illusion? (2018) (12)
Amyloid imaging with Pittsburgh Compound B (2005) (12)
Biopsy support for the validity of Pittsburgh compound B positron emission tomography with a twist. (2008) (12)
Peripheral inflammatory biomarkers predict the deposition and progression of amyloid-β in cognitively unimpaired older adults (2021) (12)
The AT(N) framework for Alzheimer's disease in adults with Down syndrome. (2020) (12)
Predicting Symptom Onset in Sporadic Alzheimer Disease With Amyloid PET (2021) (12)
Predicting positivity for a new era of Alzheimer disease prevention trials (2012) (11)
11 C PiB and Structural MRI Provide Complementary Information in Imaging of AD and Amnestic MCI (2009) (11)
Amyloid Imaging with PET in Alzheimer’s Disease, Mild Cognitive Impairment, and Clinically Unimpaired Subjects (2009) (11)
Aggregation of beta-amyloid peptide is promoted by membrane phospholipid metabolites elevated in Alzheimer's disease brain. (1997) (11)
Modeling autosomal dominant Alzheimer's disease with machine learning (2021) (11)
Small molecule beta-amyloid probes which distinguish homogenates of Alzheimer's and control brains (1994) (11)
Comparison of longitudinal Aβ in nondemented elderly and Down syndrome (2019) (11)
Impact of partial volume correction on the regional correspondence between in vivo [C-11]PiB PET and postmortem measures of Aβ load (2018) (11)
Comparing amyloid-β plaque burden with antemortem PiB PET in autosomal dominant and late-onset Alzheimer disease (2021) (10)
Whatever happened to Pittsburgh Compound-A? (2008) (10)
Hippocampal sclerosis, TDP‐43, and the duration of the symptoms of dementia of AD patients (2020) (10)
Structural determinants of activity at the GABAB receptor. A comparison of phosphoethanolamine and related GABA analogs. (1995) (10)
Antioxidant activity of X-34 in synaptosomal and neuronal systems (2003) (10)
An Aβ Sequestration Approach Using Non-Antibody Aβ Binding Agents (2005) (9)
Where is hippocampal activity in the cascade of Alzheimer's disease biomarkers? (2015) (9)
Relationships Between Executive Control Circuit Activity, Amyloid Burden, and Education in Cognitively Healthy Older Adults. (2019) (9)
The Centiloid Scale: Standardization of amyloid imaging measures (2013) (9)
PET measurement of longitudinal amyloid load identifies the earliest stages of amyloid-beta accumulation during Alzheimer’s disease progression in Down syndrome (2021) (9)
Relationship of amyloid-β1–42 in blood and brain amyloid: Ginkgo Evaluation of Memory Study (2019) (9)
A randomized controlled trial of amyloid positron emission tomography results disclosure in mild cognitive impairment (2020) (9)
Filamentous proteins in Alzheimer's disease: new insights through molecular biology. (1988) (9)
PiB and structural MRI provide complementary information in imaging of Alzheimer ’ s disease and amnestic mild cognitive impairment (2008) (9)
Leisure Activity, Brain β‐amyloid, and Episodic Memory in Adults with Down Syndrome (2019) (9)
Alkyl-substituted γ-butyrolactones as potential tools in the study and treatment of epilepsy (1983) (9)
Quantitative and statistical analyses of PET imaging studies of amyloid deposition in humans (2004) (9)
Synergism of antihypertensives and cholinesterase inhibitors in Alzheimer's disease (2018) (9)
Predicting resistance to amyloid-beta deposition and cognitive resilience in the oldest-old (2020) (8)
The effect of amyloid deposition on longitudinal resting-state functional connectivity in cognitively normal older adults (2020) (8)
Endogenous murine Aβ increases amyloid deposition in APP23 but not in APPPS1 transgenic mice (2015) (8)
A survey of attitudes toward clinical trials and genetic disclosure in autosomal dominant Alzheimer’s disease (2015) (8)
Comparison of the binding of 3′-F-PiB and PiB in human brain homogenates (2008) (8)
CONVERSION OF AMYLOID QUANTITATION WITH FLORBETAPIR SUVR TO THE CENTILOID SCALE (2016) (7)
White matter microstructure associations with episodic memory in adults with Down syndrome: a tract-based spatial statistics study (2021) (7)
Blood and CSF biomarkers for AD revisited: what’s new, what’s good, and is this where we should be looking? (2002) (7)
Amyloid-beta imaging in older adults presenting to a memory clinic with subjective cognitive decline (2015) (7)
Development of a PET radioligand selective for cerebral amyloid angiopathy. (2020) (7)
Amyloid Imaging and (What is “Normal”?) Aging (2009) (7)
Associations of equol‐producing status with white matter lesion and amyloid‐β deposition in cognitively normal elderly Japanese (2020) (7)
O3-03-05 Human amyloid-imaging studies in controls, mild cognitive impairment and Alzheimer's disease using Pittsburg compound-B (2004) (7)
P2-178 Species-dependent formation and identification of the brain metabolites of the amyloid imaging agent [11C]PIB (2004) (7)
Patterns of glucose hypometabolism in Down syndrome resemble sporadic Alzheimer's disease except for the putamen (2020) (7)
Association between Brain Amyloid, White Matter Hyperintensities and Hypometabolism, and Progression to Mild Cognitive Impairment in Cognitively Normal Individuals. (2019) (6)
Detection of Brain Tau Pathology in Down Syndrome Using Plasma Biomarkers (2022) (6)
Association Between Amyloid-β, Small-vessel Disease, and Neurodegeneration Biomarker Positivity, and Progression to Mild Cognitive Impairment in Cognitively Normal Individuals (2019) (6)
Effect of phosphomonoesters, phosphodiesters, and phosphocreatine on glutamate uptake by synaptic vesicles. (1997) (6)
Correction: Quantitative Amyloid Imaging in Autosomal Dominant Alzheimer’s Disease: Results from the DIAN Study Group (2016) (6)
The role of membranes and energetics in Alzheimer disease (1994) (6)
Physical activity and cognitive and imaging biomarkers of Alzheimer's disease in down syndrome (2021) (5)
Robust White Matter Hyperintensity Segmentation On Unseen Domain (2021) (5)
Neurofibrillary tau depositions emerge with subthreshold cerebral beta-amyloidosis in down syndrome (2021) (5)
Research Use of Ecological Momentary Assessment for Adverse Event Monitoring Following Amyloid-β Results Disclosure (2019) (5)
Human amyloid-imaging studies with Pittsburgh Compound-B in mild cognitive impairment (MCI): Is MCI the critical period of amyloid plaque deposition? (2005) (5)
Amyloid and neurodegeneration (2013) (5)
Alzheimer’s disease pathology in a community-based sample of older adults without dementia: The MYHAT neuroimaging study (2020) (5)
An Abeta sequestration approach using non-antibody Abeta binding agents. (2005) (5)
11C-PIB PET imaging in the differential diagnosis of dementia (2006) (5)
Presymptomatic Alzheimer's disease in the Dominantly Inherited Alzheimer's Network (DIAN) (2012) (5)
In vivo evaluation and imaging of a lipophilic derivative of Congo red for amyloid assessments (2001) (4)
Synthesis and evaluation of a radioiodinated benzothiazole derivative as a radioligand for in vivo quantitation of β‐amyloid deposits in aging and alzheimer's disease (2001) (4)
Synthesis and β-amyloid binding properties of rhenium 2-phenylbenzothiazoles (2009) (4)
P1-256: Cerebellar amyloid in a case of early-onset dementia with a presenilin-1 mutation: Correlation to clinical phenotype (2008) (4)
Amyloid deposition is associated with different patterns of hippocampal connectivity in men versus women (2019) (4)
Simplified quantification of PIB amyloid imaging PET studies (2005) (4)
Effects of alkyl-substituted γ-butyrolactones and succinimides on the evoked and spontaneous activity of hippocampal slices in vitro (1983) (4)
Optimal time window for standardized uptake ratio as a simplified measure of PIB retension (2007) (4)
[12] - Magnetic Resonance Spectroscopy of Neural Tissue (1996) (4)
In vivo amyloid deposition and neuropathological findings after humanized amyloid β-specific monoclonal antibodies therapy in a patient with Alzheimer's disease (2009) (4)
ALPHA-SUBSTITUTED Γ-BUTYROLACTONES: NEW CLASS OF ANTICONVULSANT DRUGS (1983) (3)
Neuroimaging within the Dominantly Inherited Alzheimer’s Network (DIAN): PET and MRI (2022) (3)
P-029 Correlation of regional in VIVO pittsburgh compound-B (PIB) retention with in vitro PIB, Aβ levels, and amyloid plaque density: Validation of PIB-PET in postmortem human brain (2007) (3)
Genetic risk for attention-deficit/hyperactivity disorder predicts cognitive decline and development of Alzheimer’s disease pathophysiology in cognitively unimpaired older adults (2022) (3)
11C-PiB PET can underestimate brain amyloid-β burden when cotton wool plaques are numerous. (2021) (3)
Arterial stiffness is associated with amyloid deposition in the brain independent of blood pressure (2013) (3)
AMYLOID- β ASSOCIATIONS WITH WHITE MATTER IN DOWN SYNDROME ASSESSED USING TRACT-BASED SPATIAL STATISTICS (TBSS) AND 11C-PIB POSITRON EMISSION TOMOGRAPHY (2019) (3)
The Relationship of Current Cognitive Activity to Brain Amyloid Burden and Glucose Metabolism. (2018) (3)
Anomalous PiB enhancement in the Superior Sagittal and Transverse Venous Sinuses (2012) (3)
Direct Correlations of [H-3]Flutemetamol Binding with [H-3]PiB Binding and Amyloid-beta Concentration and Plaque Load in [C-11]PiB Imaged Brains (S34.002) (2012) (3)
Chrysamine G and its derivative reduce amyloid beta-induced neurotoxicity in mice. (2002) (3)
Nuclear Magnetic Resonance Study of Phospholipid Metabolites in Alzheimer’s Disease (1990) (2)
Support vector machine learning and diffusion-derived structural networks predict amyloid quantity and cognition in adults with Down's syndrome (2022) (2)
Quantitative in vitro NMR analysis of Alzheimer's, non-Alzheimer's demented and control brain (1994) (2)
The roles of study setting, response bias, and personality in subjective memory complaints of cognitively normal older adults (2020) (2)
Longitudinal PIB measures in control, MCI, and AD subjects (2008) (2)
Statistical Methods for Processing Neuroimaging Data from Two Different Sites with a Down Syndrome Population Application (2020) (2)
Comparison of amyloid burden in individuals with Down syndrome versus autosomal dominant Alzheimer's disease: a cross-sectional study (2023) (2)
STANDARDIZATION OF AMYLOID PET: THE CENTILOID PROJECT (2014) (2)
Elevated PiB precedes dementia in autosomal dominant Alzheimer's disease: PiB, FDG and atrophy in the DIAN cohort (2012) (2)
O2-01-05 Incident psychiatric symptoms predict conversion to dementia in mild cognitive impairment subgroups (2004) (2)
Multi-Domain Learning By Meta-Learning: Taking Optimal Steps In Multi-Domain Loss Landscapes By Inner-Loop Learning (2021) (2)
Quantitative PET and Histology of Brain Biopsy Reveal Lack of Selective Pittsburgh Compound-B Binding to Intracerebral Amyloidoma. (2018) (2)
IC-103-05 Pittsburgh compound-B four years later: What have we learned, what lies ahead? (2006) (2)
Disclosing amyloid imaging results in MCI: What do patients and families want, and why? (2013) (2)
The nature of behavioral disorders in human Klüver-Bucy syndrome (1995) (2)
P1-231: Correlation of amyloid deposition with local and distal glucose metabolism in cognitively normal elderly, MCI and Alzheimer's disease (2008) (2)
Comparative evaluation of template-based region sampling for PiB PET data analysis (2010) (2)
PiB-PET detects transthyretin-related cerebral amyloid angiopathy (2016) (2)
In Vivo Fibrillar (cid:2) -Amyloid Detected Using [ 11 C]PiB Positron Emission Tomography and Neuropathologic Assessment in Older Adults (2011) (2)
An atlas of cortical circular RNA expression in Alzheimer disease brains demonstrates clinical and pathological associations (2019) (2)
Comparison of amyloid burden in individuals with Down syndrome versus autosomal dominant Alzheimer's disease: a cross-sectional study (2023) (2)
X-34 and other congo red-type amyloid binding agents as in vivo amyloid probes (2000) (2)
Development of Benzothiazole Amyloid-Imaging Agents (2004) (2)
IC-103-04 Amyloid burden correlates with cognitive function in normal aging, MCI and AD (2006) (2)
Use of PONS as a normalizing region for [c-11]pib-pet scans: Effect on subject classification (2011) (2)
Imaging the pathology of Alzheimer’s disease: Building on a century-Old blueprint (2006) (2)
Development of a standardized approach to disclosing amyloid imaging results in MCI (2012) (2)
First PET Study with a Benzothiazol Amyloidimaging Agent (PIB) in Alzheimer’s Disease Patients and Healthy Volunteers (2004) (2)
LONGITUDINAL CHANGE OF NEUROIMAGING AND CLINICAL MARKERS IN AUTOSOMAL DOMINANT ALZHEIMER'S DISEASE (2014) (2)
Reversal of the anticonvulsant action of ethosuximide by drugs that diminish CNS dopaminergic neurotransmissions (1980) (1)
O3-03-04 Novel approaches for non-invasive optical detection of amyloid-β plaques in vivo (2004) (1)
Potential utility of plasma p-tau and NfL as surrogate biomarkers for preventive clinical trials (2022) (1)
Amyloid imaging of cerebral amyloid angiopathy (2007) (1)
Attitudes toward clinical trials and genetic disclosure in autosomal dominant Alzheimer’s disease (2015) (1)
FDG-PET and amyloid imaging in the dominantly inherited Alzheimer network (2011) (1)
O3-01-02 Early, premorbid detection of beta-amyloid pathology by non-invasive in vivo quasi-elastic light scattering in the lens (2006) (1)
Low binding of the amyloid PET tracer, PIB, to transgenic PS1/APP mouse brain compared to human AD brain explained by Bmax (2005) (1)
Physical activity, memory function, and hippocampal volume in adults with Down syndrome (2022) (1)
IC-P-016 Imaging of cerebral amyloid angiopathy with Pittsburgh compound B (2006) (1)
In Pre-Clinical AD Small Vessel Disease is Associated With Altered Hippocampal Connectivity and Atrophy. (2022) (1)
INCREASES IN PIB RETENTION ARE ASSOCIATED WITH INCREASED CEREBRAL GLUCOSE METABOLISM IN COGNITIVELY NORMAL ELDERLY: ROLE FOR COMPENSATORY HYPERMETABOLISM? (2016) (1)
Development, initial validation, and application of a visual read method for [18F]MK‐6240 tau PET (2023) (1)
Characterization of point-spread function specification error on Geometric Transfer Matrix partial volume correction in [11C]PiB amyloid imaging (2021) (1)
Relationship between Hippocampal Sclerosis and TDP-43, and Duration of the Symptoms of Dementia in Alzheimer’s Disease Patients (S39.003) (2016) (1)
Positron emission tomography imaging of amyloid-beta plaque deposition: a decade of translation (2012) (1)
Positron emission tomography imaging of amyloid-beta plaque deposition: a decade of translation (2012) (1)
Pharmacologic and pharmacokinetic equivalence studies of GE-067 to PiB (2009) (1)
P2-285 Voxel-based analyses of pittsburgh Compound-B and FDG in AD (2006) (1)
RESPONSE LETTER TO DR. THOMAS FINUCANE (2005) (1)
Conversion to MCI and amyloid-positivity in normal controls (2013) (1)
Cortical atrophy and amyloid and tau deposition in Down syndrome: A longitudinal study (2022) (1)
Subjective cognition and ‘neuroticism,' but not depressive symptoms, are associated with beta-amyloid deposition in cognitively normal elderly (2013) (1)
Cerebral Amyloid Related Alterations in Neuronal Metabolism and the Contribution of Multimodal Measures of Vascular Function. (S8.003) (2014) (1)
BINDING OF PITTSBURGH COMPOUND B TO BOTH NORMAL AND ABNORMAL WHITE MATTER IN ELDERLY COGNITIVELY NORMAL CONTROL (2014) (1)
Evaluation of amyloid and tau PET quantitation methods using a 3D‐printed anatomically accurate brain phantom (2020) (1)
P1-379: In vivo detection of Alzheimer's disease–linked Aβ peptide accumulation in the lens (2008) (1)
IC-P-127 Non-invasive early detection of beta-amyloid molecular pathology by quasi-elastic light scattering in vivo (2006) (1)
PIB PET 3-site stability study (2007) (1)
[11C]PIB imaging in primary progressive aphasia and Alzheimer disease (2007) (1)
ASSOCIATIONS BETWEEN Aβ AND TAU IN ADULTS WITH DOWN SYNDROME (2019) (1)
BETA-AMYLOID DEPOSITION AND SUSPECTED NON-ALZHEIMER'S PATHOPHYSIOLOGY (SNAP) EXHIBIT DIFFERENT DECLINE PATTERNS AMONG COGNITIVE DOMAINS (2016) (1)
Amyloid imaging with Pittsburgh Compound-B in late-life depression (2005) (1)
PYROGLUTAMATE AND FULL-LENGTH AMYLOID-B CONCENTRATIONS IN THE SUPERIOR FRONTAL CORTEX ACROSS CLINICAL STAGES OF ALZHEIMER’S DISEASE (2016) (1)
Histological characterization of PIB binding to amyloid plaques in Alzheimer’s disease (2005) (1)
Brain health correlates of mobility-related confidence (2022) (1)
SLEEP, COGNITION, AND β-AMYLOID IN ADULTS WITH DOWN SYNDROME (2019) (1)
An Effect of Education on Memory-Encoding Activation in Subjective Cognitive Decline. (2021) (1)
Predicting the time to tau onset in Down syndrome using amyloid chronicity (2020) (1)
An accurate and computationally efficient method for voxel-by-voxel estimation of the Pittsburgh compound B distribution volume ratio (2008) (1)
Role of tau deposition in early cognitive decline in Down syndrome (2022) (1)
Elevated PiB precedes dementia in autosomal-dominant Alzheimer's disease: PiB, FDG and atrophy in the DIAN cohort (2012) (0)
Sensitivity, Specificity and Reliability of Three Pathological Criteria for Alzheimer’s Disease (P6.223) (2016) (0)
omarker for assessing signals of efficacy in early-stage AD clinical trials. P2-327 NEUROIMAGE STEREOLOGY: A MARKER FOR BRAIN AGING AND DEMENTIA (2006) (0)
APOEÏµ4 carriership associates with microglial activation independently of AÎ² plaques and tau tangles (2022) (0)
SPATIAL ASSOCIATIONS OF Aβ WITH TAU DEPOSITION IN DOWN SYNDROME (2019) (0)
Imaging amyloid: Now that we can see it, what does it all mean? (2009) (0)
Elevated neurofibrillary tau levels emerge with subthreshold Aβ accumulation in Down syndrome (2021) (0)
Evaluation of PVC methods on head‐to‐head FTP and MK6240 (2022) (0)
White matter microstructure and episodic memory in adults with down syndrome: A Tract‐Based Spatial Statistics (TBSS) Study (2020) (0)
Opening Mechanotransducer Channels (2005) (0)
Commentary on “Diagnosis of Alzheimer’s disease: Two decades of progress.” Diagnosis of Alzheimer’s disease: Walking a well-paved path (2005) (0)
COMPARISON OF IN VIVO [F-18]AV-1451 OFF-TARGET RETENTION IN AFRICAN-AMERICANS AND CAUCASIANS (2018) (0)
ALZHEIMER’S DISEASE PATHOLOGY IN A COMMUNITY-BASED SAMPLE OF OLDER ADULTS WITHOUT DEMENTIA: A POPULATION-NEUROSCIENCE APPROACH (2019) (0)
P2-329 Amyloid burden correlates with cognitive function in normal aging, MCI and AD (2006) (0)
P164. Investigation of noise-induced correlations in dual-biomarker parametric imaging from dynamic [C]PiB PET (2016) (0)
CONCURRENT EEG/FMRI NETWORK DYNAMICS ALTERATIONS IN COGNITIVELY INTACT INDIVIDUALS AT RISK FOR ALZHEIMER’S DISEASE (2019) (0)
Longitudinal Changes in Amyloid Deposition in Normal Elderly, Mild Cognitive Impairment and Alzheimer's disease (2010) (0)
Radiosynthesis, in vitro and in vivo evaluations of [3H]/[18F]CBD-2115 as first in class radiotracers for imaging 4R-tauopathies (2021) (0)
Performance of plasma amyloid, tau, and astrocyte biomarkers to identify cerebral AD pathophysiology (2022) (0)
411 Chrysamine G and congo red inhibit aggregation of β-amyloid, maintaining its protease-sensitive conformation (1996) (0)
Use of pons as a normalizing region for [C-11]PIB PET scans: Effect on subject classification (2011) (0)
HYPERCAPNIA EXPOSES DEFICIENCIES IN CEREBROVASCULAR RESPONSE AND TISSUE OXYGENATION IN TRANSGENIC AD MICE (2018) (0)
Another data/rhetoric mismatch on donepezil. Authors' reply (2005) (0)
P2-369 Correlation analysis of the histofluorescence of an analogue of Pittsburgh Compound-B and Aβ peptide levels in Alzheimer’s disease (2006) (0)
Template based PiB PET-image analysis: Template driven variability (2010) (0)
Correspondence between blood‐based amyloid‐β by immuno‐precipitation mass spectrometry and PIB‐PET imaging in a population cohort (2020) (0)
Title A survey of attitudes toward clinical trials and genetic disclosure in autosomal dominant Alzheimer ' s disease (2015) (0)
O1-05-01 (2006) (0)
Functional connectivity measurements in APP/PS‐1 mice revealed hypo‐connectivity with transient hyper‐connectivity (2021) (0)
EARLY RECOGNITION AND TREATMENT OF ALZHEIMERʼS DISEASE: WHATʼS NEW? WHATʼS CONTROVERSIAL? WHATʼS PRACTICAL? (1999) (0)
P4-123 PrPSc Aggregates in the ocular lens of symptomatic and pre-symptomatic prion infected mice (2006) (0)
Longitudinal head-to-head comparison of 11C-PiB and 18F-florbetapir PET in a Phase 2/3 clinical trial of anti-amyloid-β monoclonal antibodies in dominantly inherited Alzheimer's disease. (2023) (0)
Cognitive follow-up in non-demented subjects with evidence of amyloid deposition using Pittsburgh Compound-B (PIB) (2007) (0)
IC-P2-102: Differential labeling of amyloid plaques and tangles with 6-CN-PiB: Implications for in vivo PiB PET imaging (2008) (0)
IC-P-001 Imaging Alzheimer’s pathology in late-life depression with PIB-PET (2006) (0)
Subjective cognition and neuroticism, but not depressive symptoms, are associated with beta-amyloid deposition in the cognitively normal elderly (2013) (0)
Semi‐quantitative [11C]PiB and [15O]H2O PET measures of cerebrospinal fluid dynamics discriminate amyloid load but not cognitive status (2021) (0)
White matter microstructure associations to amyloid burden in adults with Down syndrome (2021) (0)
Plasma biomarkers of brain amyloid‐β and tau pathologies in Down syndrome (2022) (0)
Binding of the amyloid-imaging PET tracer, Pittsburgh Compound-B, to post-mortem human brain tissue from the AN-1792 immunotherapy trial (2005) (0)
Regional FDG hypometabolism associated with amyloid deposition in normal aging (2007) (0)
In vivo Detection of Early Alzheimer's Disease-Linked Aβ Peptide Accumulation in the Lens by Non-Invasive Quasi-Elastic Light Scattering (2010) (0)
Patterns of correlation between Aβ deposition and glucose metabolism across the spectrum of mild cognitive impairment to Alzheimer's disease (2009) (0)
Physical activity, cognitive decline and biomarkers of Alzheimer’s disease in adults with Down syndrome (2021) (0)
β-amyloid plaques in a PiB-PET negative subject: Implications for sensitivity of amyloid imaging in vivo (2009) (0)
An MRI multi‐scanner neuroimaging data harmonization study using RAVEL and ComBat (2021) (0)
Alkyl-substituted gamma-butyrolactones as potential tools in the study and treatment of epilepsy. (1983) (0)
O2-03-05 Early detection of Alzheimer’s disease-linked aβ peptide accumulation in the lens by non-invasive quasi-elastic light scattering (2007) (0)
IC-P-012 CONFOCAL ANALYSIS OF FLUORESCENT SIGNAL DERIVED FROM CN-FLUTEMETAMOL LABELED DIFFUSE AND NEURITIC PLAQUES IN ALZHEIMER’S DISEASE (2018) (0)
Early striatal amyloid signal in Down Syndrome: Comparison of PiB and Florbetapir PET (2022) (0)
Toronto 07 : 30 – 08 : 00 Registration and Continental Breakfast 08 : 00 – 08 : 15 Introduction 08 : 15 – 09 : 30 Session 1 : Pathologic Correlations , Amyloid Positivity (2010) (0)
Tau imaging : pathologic correlations 3 Number of words in the body of the manuscript : 3535 Number of figures : 5 Number of color figures : 4 Number of tables : 0 (2016) (0)
Regional correspondence of antemortem and postmortem amyloid load (2011) (0)
WHY FEW COGNITIVELY OLD BE TO PREVENTING DEMENTIA, ALZHEIMER’S POLYGENETIC RISK FOR ALZHEIMER’S DISEASE AND DEMENTIA STATUS HEARING LOSS PREVALENCE AND ITS ASSOCIATION WITH DEMENTIA: A CROSS-SECTIONAL POPULATION-BASED STUDY (2019) (0)
VERBAL ASSOCIATIVE BINDING IS ASSOCIATED WITH AMYLOID-BETA DEPOSITION IN SELF-REFERRED SUBJECTIVE MEMORY COMPLAINERS BUT NOT IN COGNITIVELY NORMAL VOLUNTEERS (2016) (0)
Amyloid imaging in nondemented oldest old (2011) (0)
Longitudinal PET imaging identifies earliest stages of Aβ accumulation in Down syndrome (2021) (0)
IC-P2-124: Gray matter changes in cognitively normal control subjects with PiB retention (2008) (0)
Early striatal amyloid deposition distinguishes down syndrome and autosomal dominant Alzheimer’s disease from late-onset amyloid deposition (2015) (0)
Effect of cognitively stimulating activities on PiB-PET in cognitively normal elderly (2015) (0)
Genetic risk for attention‐deficit/hyperactivity disorder is associated with amyloid‐dependent cognitive decline in older adults (2022) (0)
COMPARING THE CENTILOID SCALE FOR PITTSBURGH COMPOUND B AND FLORBETAPIR IN LONGITUDINAL PET STUDIES OF SPORADIC AD (2018) (0)
CORRESPONDENCE BETWEEN [C-11]PIB PET AND POST-MORTEM MEASURES OF AMYLOID LOAD IN THE PRECUNEUS: THE ROLE OF DIFFUSE Aβ PLAQUES (2014) (0)
Impact of meningeal and age‐related off‐target binding on longitudinal [18F]MK6240 quantification. (2022) (0)
Characteristics of brain morphology in dementia patients from an ADRC (2011) (0)
SHORT-TERM OUTCOMES OF A RANDOMIZED CONTROLLED TRIAL OF AMYLOID PET RESULTS DISCLOSURE IN MILD COGNITIVE IMPAIRMENT (2019) (0)
470. No increased severity of neuropathologic features in Alzheimer’s disease with psychosis (2000) (0)
AMYLOID BURDEN AND CORTICAL ATROPHY IN NON-DEMENTED DOWN SYNDROME (2018) (0)
Sources of variability in the PIB PET tissue time–activity data (2008) (0)
COMPARISON OF IN VIVO [F-18]AV-1451 OFF-TARGET RETENTION IN AFRICAN AMERICANS AND CAUCASIANS (2018) (0)
The location of PSEN1 pathogenic variants in transmembrane vs. cytoplasmic domains may alter neurodegenerative and cognitive trajectories: Findings from the DIAN study (2021) (0)
PREDICTING RESILIENCY AGAINST AMYLOID-BETA DEPOSITION, COGNITIVE IMPAIRMENT, AND THEIR COMBINATION IN THE OLDEST-OLD (2018) (0)
dominant Alzheimer disease Cerebral perfusion alterations and cerebral amyloid in autosomal (0)
Amyloid imaging in nondemented oldest-old (2011) (0)
Early Striatal Perfusion Deficits in Autosomal Dominant Alzheimer Disease Detected with Arterial Spin Labeled MRI. (P6.311) (2014) (0)
Comparison of longitudinal [11C]PiB change measures and impact of CSF dilution correction (2011) (0)
JAMA Paper supplement (2015) (0)
Cerebral amyloid-associated changes in brain perfusion in autosomal dominant Alzheimer's disease (2013) (0)
Editorial Board (2011) (0)
Relationships among Potential Precursors of Dementia: Subjective Cognitive Decline, Amyloid Burden, and Brain Hyperactivation (2018) (0)
Regional correspondence of ante-mortem and post-mortem amyloid load (2011) (0)
P2-268 Amyloid deposition in presymptomatic familial Alzheimer’s disease (2006) (0)
Cognitive trajectories associated with beta-amyloid deposition in the nondemented oldest-old (2012) (0)
BINDING OF PITTSBURGH COMPOUND B TO BOTH NORMAL AND ABNORMAL WHITE MATTER IN ELDERLY COGNITIVELY NORMAL CONTROLS (2014) (0)
P2-328 Imaging of cerebral amyloid angiopathy with Pittsburgh Compound B (2006) (0)
Impact of meningeal and age‐related off‐target binding on longitudinal [18F]MK6240 quantification (2022) (0)
Sex and cerebral small vessel disease‐specific longitudinal trajectories of amyloid, tau, and neurodegeneration (2021) (0)
Pittsburgh compound-B does not detect cotton wool plaques in PS-1 mutation carriers (2013) (0)
CORRESPONDENCE BETWEEN [C-11]PIB PET AND POST-MORTEM MEASURES OF AMYLOID LOAD IN THE PRECUNEUS: THE ROLE OF DIFFUSE AB PLAQUES (2014) (0)
CAN WE VISUALIZE PLAQUES AND TANGLES IN VIVO? A LOOK TO THE FUTURE (1999) (0)
S2-04-04 Imaging and therapeutic approaches for β-sheet structures in prion and Alzheimer's diseases (2004) (0)
IC-P-019 LONGITUDINAL ACCUMULATION OF b AMYLOID ON PET IN DEMENTIAWITH LEWY BODIES AND RELATIONSHIP TO CLINICAL DISEASE PROGRESSION PREDICTING RESILIENCYAGAINST AMYLOID-BETA DEPOSITION, COGNITIVE IMPAIRMENT, AND THEIR COMBINATION IN THE OLDEST-OLD (2018) (0)
CSF BIOMARKERS IN DOWN SYNDROME (2019) (0)
Synthesis and structure-activity relationship of Tc/Re 2-arylbenzothiazoles as {beta}-amyloid imaging agents (2012) (0)
The effect of amyloid deposition on longitudinal resting-state functional connectivity in cognitively normal older adults (2020) (0)
Trans-cortical correlations of pittsburgh compound-B in cognitively normal elderly, MCI and Alzheimer's: Implications for the natural history of amyloid deposition (2010) (0)
Cluster analysis of PIB and FDG PET measures in control, MCI, and Alzheimer's disease subjects (2008) (0)
IN VIVO NADH FLUORESCENCE IMAGING OF DOUBLE TRANSGENIC ALZHEIMER'S DISEASE MICE REVEALS CHRONIC TISSUE HYPOXIA (2016) (0)
O1-05-01 Cortical amyloid deposition related to failure of hippocampal activation (2007) (0)
Effect of cognitively and physically stimulating activities on PiB-PET (2013) (0)
ASSESSMENT OF LONGITUDINAL AMYLOID LOAD CHANGE IN DOWN SYNDROME (2019) (0)
PREDICTING RESILIENCY AGAINST AMYLOID-BETA DEPOSITION, COGNITIVE IMPAIRMENT, AND THEIR COMBINATION IN THE OLDEST-OLD (2018) (0)
Amyloid- β and tau deposition influences cognitive and functional decline in Down syndrome (2022) (0)
O3-06-08 Pattern of amyloid plaque deposition with Pittsburgh compound-B (PIB) in mild cognitive impairment (2006) (0)
The application of amyloid-imaging to the diagnosis and treatment of Alzheimer’s disease (2005) (0)
Trans-cortical correlations of Pittsburgh Compound-B in cognitively normal elderly, MCI and AD: Implications for the natural history of amyloid deposition (2010) (0)
In Vivo Imaging of Alzheimer Pathology in Transgenic Mice using Multiphoton Microscopy (2004) (0)
Evaluation of A Direct Regional Reprojection Reconstruction Method to Improve Quantitation of Amyloid and Tau PET Images using 3D Printed Phantoms (2022) (0)
Blood-brain barrier integrity impacts the use of plasma amyloid-β as a proxy of brain amyloid-β pathology. (2023) (0)
Imaging the Pathology of Alzheimer's Disease: Amyloid-Imaging with PET (2003) (0)
Amyloid Load in the Down syndrome population measured with [11C]PiB PET (2019) (0)
P2-019: Differential labeling of amyloid plaques and tangles with 6-CN-PiB: Implications for in vivo PiB PET imaging (2008) (0)
Comparing Pathological Risk Factors for Dementia between Cognitively Normal Japanese and Americans (2021) (0)
P3-440 COMPARINGTHECENTILOID SCALEFOR PITTSBURGH COMPOUND B AND FLORBETAPIR IN LONGITUDINAL PET STUDIES OF SPORADIC AD (2018) (0)
Evaluating Template Generation Methods for Spatially Normalizing Down Syndrome Brain Magnetic Resonance Images (2022) (0)
Multivariate analysis of PIB PET imaging studies (2006) (0)
Use of partial least squares to relate yearly PiB DVR to clinical covariates in non-demented subjects (2009) (0)
COMPARATIVE ANALYSIS OF PIB IN VIVO WITH 6-CN-PIB AND Aβ-IMMUNOHISTOCHEMISTRY POSTMORTEM IN FAMILIAL ALZHEIMER DISEASE ASSOCIATED WITH THE PSEN1 I229F MUTATION (2014) (0)
COGNITIVE IMPAIRMENTAND INCREASED ALZHEIMER’S-LIKE PATHOLOGY IN CRND8 APP TRANSGENIC MICE (2013) (0)
Characterization and Non–Invasive Imaging of Lens ß–Amyloid in the Tg2576 Mouse Model of Alzheimer's Disease (2005) (0)
LOWER REGIONAL β-AMYLOID BURDEN IN JAPANESE THAN AMERICAN APOE ε4-NEGATIVE ELDERLY (2019) (0)
IC-P-210 COMPARISON OF IN VIVO [F-18]AV-1451 OFF-TARGET RETENTION IN AFRICAN- AMERICANS AND CAUCASIANS (2018) (0)
Effect of cognitively and physically stimulating activities on PiB-PET (2013) (0)
Brain PET Oral 6: Neurodegenerative Disorders (2009) (0)
A survey of attitudes toward clinical trials and genetic disclosure in autosomal dominant Alzheimer’s disease (2015) (0)
Cognitive trajectories associated with beta-amyloid deposition in the nondemented oldest-old (2012) (0)
Assessing brain amyloid in nondemented adults with Down syndrome (2012) (0)
Neural asymmetry during memory encoding and its association with markers of preclinical Alzheimers Disease (2021) (0)
HISTORY OF AMYLOID PET (2018) (0)
1008 Sleep Efficiency Moderates The Relationship Between Beta-Amyloid And Memory Retention (2018) (0)
CEREBRAL MICROBLEEDS ARE ASSOCIATED WITH CEREBRAL BLOOD FLOW AND METABOLISM BUT NOT AMYLOID BURDEN OR BRAIN ATROPHY IN COGNITIVELY NORMAL ELDERLY (2014) (0)
IN VIVO NADH FLUORESCENCE IMAGING OF DOUBLE TRANSGENIC AD MICE REVEALS CHRONIC TISSUE HYPOXIA (2016) (0)
COMPARATIVE ANALYSIS OF PIB IN VIVO WITH 6-CN-PIB AND AB-IMMUNOHISTOCHEMISTRY POSTMORTEM IN FAMILIAL ALZHEIMER'S DISEASE ASSOCIATED WITH THE PSEN1 I229F MUTATION (2014) (0)
SELECTIVITY OF PET AMYLOID IMAGING LIGANDS IN THE ALZHEIMER’S DISEASE NEUROPATHOLOGY SPECTRUM (2019) (0)
P2-097: Amyloid-imaging in dementias of uncertain etiology with Pittsburgh compound B (2008) (0)
Longitudinal study of amyloid deposition in carriers of presenilin-1, presenilin-2 and APP mutations (2009) (0)
Development and Application of b-Amyloid Imaging Agents in Alzheimer’s Disease (2016) (0)
Amyloid Deposition and Hippocampal Volume as Predictors of Incident Dementia in Non-Demented Very Elderly Subjects (IN3-2.004) (2013) (0)
LONGITUDINAL CHANGES IN BRAIN AMYLOID DEPOSITION AND COGNITIVE-MOTOR DUAL-TASK GAIT SPEED IN COGNITIVELY NORMAL AND MOBILITY UNIMPAIRED OLDER ADULTS (2018) (0)
CONVERSION OF AMYLOID QUANTITATION WITH FLORBETAPIR SUVR TO THE CENTILOID SCALE (2016) (0)
β-amyloid plaques in a PiB-PET negative subject: Implications for sensitivity of amyloid imaging in vivo (2009) (0)
O1-04-01 Quantitative evaluation of PIB PET and FDG PET in early cognitive impairment (2007) (0)
P2-186 In vivo imaging of prion amyloid deposits (2004) (0)
DO INDIVIDUALS’ VIEWS ABOUT MILD COGNITIVE IMPAIRMENT (MCI) CORRELATE WITH LONG-TERM CLINICAL OUTCOMES? (2014) (0)
PULSE WAVE VELOCITY IS ASSOCIATED WITH INCIDENT DEMENTIA AND AMYLOID DEPOSITION IN THE BRAINS OF ELDERLY ADULTS (2018) (0)
APOEε4 associates with microglial activation independently of Aβ plaques and tau tangles (2023) (0)
Comparison of plasma amyloid, tau, and astrocyte biomarkers to identify AD pathophysiology (2022) (0)
P1-128 Non-invasive early detection of beta-amyloid molecular pathology by quasi-elastic light scattering in vivo (2006) (0)
Neuropsychological profiles of asymptomatic adults with Down syndrome and evidence of amyloid deposition (2013) (0)
COMPARING THE CENTILOID SCALE FOR PITTSBURGH COMPOUND B AND FLORBETAPIR IN LONGITUDINAL PET STUDIES OF SPORADIC AD (2018) (0)
Amyloid imaging in the 80+ population and cognitive trajectories (GEMS) (2015) (0)
Increases in Pittsburgh compound B retention are associated with increased cerebral glucose metabolism in cognitively normal elderly: Role for compensatory hypermetabolism? (2012) (0)
Longitudinal changes in fibrillar amyloid-beta deposition across the cognitive spectrum: Effect of the APOE4 allele (2011) (0)
HUMAN AMYLOID IMAGING IN CONTROLS, MCI AND AD WITH THE THIOFLAVIN-T DERIVATIVE, PIB (2003) (0)
Use of thioflavin derivatives of the selected radio amyloid imaging to assess anti-amyloid therapies (2005) (0)
Characterization of flutemetamol binding in autopsy brains from [C-11]PiB imaged subjects (2011) (0)
The Association of Age-Related and Off-Target Retention with Longitudinal Quantification of [18F]MK6240 Tau PET in Target Regions (2022) (0)
Longitudinal study of amyloid deposition in carriers of presenilin-1, presenilin-2 and APP mutations (2009) (0)
Assessing the threshold for in vivo detection of amyloid-beta plaques (2010) (0)
IC-P2-110: Classification of amyloid-positivity in cognitively normal elderly controls: Comparison of objective approaches with visual reads (2008) (0)
COMPARINGTHECENTILOIDSCALEFOR PITTSBURGH COMPOUND B AND FLORBETAPIR IN LONGITUDINAL PET STUDIES OF SPORADIC AD MEMORY ACROSS ALZHEIMER’S DISEASE SPECTRUM ARE ASSOCIATED WITH PATTERNS OF ATAU PROPAGATION PREDICTED BY BRAAK STAGING (2018) (0)
Potential Utility of Plasma P-Tau and Neurofilament Light Chain as Surrogate Biomarkers for Preventive Clinical Trials. (2023) (0)
O2-03-05 (2006) (0)
CEREBRAL AMYLOID-β AND GAIT SPEED IN OLDER ADULTS WITHOUT DEMENTIA: INFLUENCE OF COGNITION AND APOE-E4 GENOTYPE (2016) (0)
A multivariate approach for mapping longitudinal changes in amyloid deposition (2010) (0)
Regional differences in amyloid load and cortical cholinergic plasticity during the progression of Alzheimer's disease (2010) (0)
CEREBRAL MICROBLEEDS ARE ASSOCIATED WITH CEREBRAL BLOOD FLOW AND METABOLISM BUT NOT AMYLOID BURDEN OR BRAIN ATROPHY IN COGNITIVELY NORMAL ELDERLY (2014) (0)
Associations between cognition, Aβ, and tau in adults with Down syndrome (2021) (0)
IC-P-004 AMYLOID BURDEN AND CORTICAL ATROPHY IN NON-DEMENTED DOWN SYNDROME USING COMPARING VISUAL SEMI-QUANTITATIVE (2018) (0)
Relationship between longitudinal changes in amyloid deposition and incident dementia in non‐demented individuals age 80+ (2022) (0)
Evaluation of PVC methods on head‐to‐head FTP and MK6240 (2022) (0)
Benzothiazolderivatforbindelser, compositions and uses thereof (2004) (0)
Comparison of amyloid accumulation between Down syndrome and autosomal‐dominant Alzheimer disease (2022) (0)
Amyloid and tau deposition influences cognitive decline in Down syndrome (2021) (0)
IC-103-03 Amyloid deposition in presymptomatic familial Alzheimer’s disease (2006) (0)
469. Evidence of increased neuronal dysfunction in Alzheimer’s disease with psychosis (2000) (0)
Post-mortem histopathology underlying β-amyloid PET imaging following flutemetamol F 18 injection (2016) (0)
Biomarker clustering in autosomal dominant Alzheimer's disease (2022) (0)
WHY FEW SURVIVE COGNITIVELY NORMAL TO VERY OLD AGE MAY BE KEY TO PREVENTING DEMENTIA, ALZHEIMER’S DISEASE (2019) (0)
Comparison of plasma amyloid, tau, and astrocyte biomarkers to identify AD pathophysiology (2022) (0)
Imaging neurodegeneration in Down syndrome: brain templates for amyloid burden and tissue segmentation (2018) (0)
P2-063 In vivo dynamics of amyloid associated neuritic dystrophy before and after anti-Aβ immunotherapy (2004) (0)
Amyloid imaging in Alzheimer’s disease and dementia with lewy bodies with 11C-PIB-PET (2005) (0)
42 The contribution of pet amyloid imaging to the study of drug effects (2012) (0)
Using radiolabeled thioflavin derivatives in amyloid imaging for evaluation of anti-amyloid therapies (2005) (0)
MOBILITY, BRAIN BLOOD FLOW, SYSTEMIC INFLAMMATION AND, CARDIAC AND ARTERIAL STIFFNESS IN COGNITIVELY NORMAL ELDERS (2018) (0)
COMPARISON OF STRIATAL LONGITUDINAL CHANGES IN AMYLOID DEPOSITION IN NON-DEMENTED ELDERLY AND DOWN SYNDROME (2018) (0)
AMYLOID BURDEN AND CORTICAL ATROPHY IN NON-DEMENTED DOWN SYNDROME (2018) (0)
Cognitive correlates of striatal amyloid deposition in preclinical and early autosomal dominant Alzheimer's disease (2013) (0)
Comparison of amyloid accumulation between Down syndrome and autosomal‐dominant Alzheimer disease (2022) (0)
White Matter Volume Predicts 1-Year Change in Mental Status in Probable Alzheimer's Disease but Not Mild Cognitive Impairment (P03.097) (2012) (0)
Characterization of flutemetamol binding in autopsy brains from [C-11]PiB-imaged subjects (2011) (0)
BOTH FULL-LENGTH AND PYROGLUTAMATE AMYLOID-BETA ARE ASSOCIATED WITH PITTSBURGH COMPOUND-B BINDING IN THE PRECUNEUS ACROSS CLINICAL STAGES OF ALZHEIMER’S DISEASE (2019) (0)
Perspective Disclosure of amyloid imaging results to research participants: Has the time come? (2013) (0)
CSF Biomarkers in Down Syndrome and Autosomal Dominant Alzheimer Disease (2021) (0)
Diffusion structural network metrics as a predictor for Alzheimer’s disease diagnosis in Down syndrome using support vector machine classification (2020) (0)
P2-312 PET imaging of microglia in a mouse model of Alzheimer’s disease (2006) (0)
CONFOCAL ANALYSIS OF FLUORESCENT SIGNAL DERIVED FROM CN-FLUTEMETAMOL LABELED DIFFUSE AND NEURITIC PLAQUES IN ALZHEIMER’S DISEASE (2018) (0)
Arterial stiffness is associated with amyloid deposition in the brain independent of blood pressure (2013) (0)
Statistical modeling of longitudinal PiB retention (2010) (0)
Multimodal magnetic resonance imaging predicts regional amyloid- β burden in the brain (2019) (0)
P2-156 Development of amyloid-imaging agents for both pet and spect (2004) (0)
P96. Interpreting the Relationship Between White Matter Hyperintensities and Amyloid Deposition Using Rectilinear Neural Networks (2022) (0)
Astrocyte reactivity influences the association of amyloid-β and tau biomarkers in preclinical Alzheimer’s disease (2023) (0)
White matter microstructure associations with episodic memory in adults with Down syndrome: a tract-based spatial statistics study (2021) (0)
Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer’s disease (2019) (0)
A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer’s disease (2020) (0)
Identifying Sex-specific Risk Architectures for Predicting Amyloid Deposition using Neural Networks (2023) (0)
Editorial Board (2011) (0)

This paper list is powered by the following services:

Other Resources About William E. Klunk

en.wikipedia.org

What Schools Are Affiliated With William E. Klunk?

William E. Klunk is affiliated with the following schools:

William E. Klunk's Academic­Influence.com Rankings